Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2000;31:2966-2970

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Estrada, C. A.
Right arrow Articles by Byrd, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Estrada, C. A.
Right arrow Articles by Byrd, J. C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Blood Thinners
Hazardous Substances DB
*WARFARIN
Related Collections
Right arrow Health policy and outcome research
Right arrow Acute Stroke Syndromes
Right arrow Embolic stroke
Right arrow Primary and Secondary Stroke Prevention
Right arrow Anticoagulants

(Stroke. 2000;31:2966.)
© 2000 American Heart Association, Inc.


Original Contributions

Anticoagulant Patient Information Material Is Written at High Readability Levels

Carlos A. Estrada, MD, MS; Mary Martin Hryniewicz, RN, MSN; Vetta Barnes Higgs, MD; Cathy Collins James C. Byrd, MD, MPH

From the East Carolina University Anticoagulation Clinic (C.A.E., M.M.H.); Brody School of Medicine at East Carolina University (V.B.H., C.C., J.C.B.); and the Clinical Information Support Office, University Health Systems (C.A.E.), Greenville, North Carolina.

Correspondence to Dr Carlos Estrada, Brody School of Medicine at East Carolina University, 600 Moye Boulevard, PCMH TA-389, Greenville, NC 27858-4353. E-mail estradac{at}mail.ecu.edu

Background—Warfarin therapy requires frequent monitoring and dose adjustment. Elderly patients with atrial fibrillation, prior stroke, and lower literacy skills may have difficulty reading brochures that explain dosing instructions, procedures to follow, and the risks and benefits of anticoagulants. In general, it is recommended that brochures be written at or below the 6th-grade level. We determined the readability of patient information material being offered to patients receiving anticoagulants.

Methods and Results—We used the SMOG grade formula to measure readability of written patient materials. We obtained 50 brochures commonly used in anticoagulation management units from industry and health advocacy groups. Patient information was related to atrial fibrillation (16%, n=8), warfarin (44%, n=22), low-molecular-weight heparins (12%, n=6), or other related topics (28%, n=14). The mean readability was found to be grade 10.7 (95% CI 10.1 to 11.2); none had a readability score at the 6th-grade level or below, 12% of the brochures had readability scores at the 7th- to 8th-grade levels (n=6), 74% at the 9th- to 12th-grade levels (n=37), and 14% at higher than 12th-grade level (n=7). The readability grade level was similar for brochures produced by industry or health advocacy groups (P=0.9) but higher for information obtained from the Internet (12.2±1.3 grades) compared with other sources (10.3±2.1 grades; P=0.01).

Conclusions—Patient education materials related to the use of anticoagulants are written at grade levels beyond the comprehension of most patients. Low-literacy brochures are needed for patients on anticoagulants.


Key Words: anticoagulants • deep vein thrombosis • health education • patient compliance • stroke prevention




This article has been cited by other articles:


Home page
Health Aff (Millwood)Home page
W. H. Shrank and J. Avorn
Educating Patients About Their Medications: The Potential And Limitations Of Written Drug Information
Health Aff., May 1, 2007; 26(3): 731 - 740.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
W. Shrank, J. Avorn, C. Rolon, and P. Shekelle
Effect of Content and Format of Prescription Drug Labels on Readability, Understanding, and Medication Use: A Systematic Review
Ann. Pharmacother., May 1, 2007; 41(5): 783 - 801.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
E. Birman-Deych, M. J. Radford, D. S. Nilasena, and B. F. Gage
Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation
Stroke, April 1, 2006; 37(4): 1070 - 1074.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Med. Inform. Assoc.Home page
A. T. McCray
Promoting Health Literacy
J. Am. Med. Inform. Assoc., March 1, 2005; 12(2): 152 - 163.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
R. E Ferner
Is concordance the primrose path to health?
BMJ, October 11, 2003; 327(7419): 821 - 822.
[Full Text] [PDF]


Home page
JRSMHome page
S. Nadar, N. Begum, B. Kaur, S. Sandhu, and G. Y H Lip
Patients' understanding of anticoagulant therapy in a multiethnic population
J R Soc Med, April 1, 2003; 96(4): 175 - 179.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
M. M Koo, I. Krass, and P. Aslani
Factors Influencing Consumer Use of Written Drug Information
Ann. Pharmacother., February 1, 2003; 37(2): 259 - 267.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
G. Eysenbach, J. Powell, O. Kuss, and E.-R. Sa
Empirical Studies Assessing the Quality of Health Information for Consumers on the World Wide Web: A Systematic Review
JAMA, May 22, 2002; 287(20): 2691 - 2700.
[Abstract] [Full Text] [PDF]